+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immunocytokines Market by Indication, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030

  • PDF Icon


  • 205 Pages
  • January 2021
  • Region: Global
  • Roots Analysis
  • ID: 5306193


Cancer is one of the leading causes of death worldwide, accounting for an estimated 0.6 million deaths in 2020, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70%, worldwide, over the next 20 years. It is a well-known fact that the conventional treatment options, such as chemotherapy, radiation therapy, and surgery, demonstrate limited efficacy in late-stage cancers. Moreover, the non-specific and highly toxic nature of traditional chemotherapy and radiation therapy, have been demonstrated to have detrimental effects on patients’ quality of life. Amongst the emerging class of targeted anti-cancer therapies, immunotherapy has emerged as a versatile option, having demonstrated the capability to selectively target and eliminate tumor cells. As a result, such products have favorable side effects profiles. For instance, immune check point inhibitors (such as atezolizumab, nivolumab, and pembrolizumab) have been demonstrated to offer long term clinical benefits to patients suffering from metastatic tumors. Similarly, other immunotherapies, such as dendritic cell therapy, T cell receptor transduced T cells, and chimeric antigen receptor (CAR)-modified T cells have shown promising results in eradicating primary and metastasized cancer cells. However, these therapies have been associated with severe and often life-threatening side effects, such as cytokine storm. Moreover, for T-cell therapies, mispairing of endogenous and transfected TCR α and β chains have been demonstrated to have detrimental biological effects. 

Traditionally, cytokines have been investigated as a therapeutic modality across multiple clinical trials, particularly as anti-cancer agents. However, the systemic administration of such potent, biologically-active molecules has been shown to be associated with a wide range of dose-dependent side effects and unfavorable pharmacokinetic properties, which, in a way, hinders dose escalation to therapeutically beneficial levels. To overcome the treatment-limiting toxicities of cytokines, researchers are now focusing on immunocytokines. Immunocytokines are fusion proteins, featuring the target specificity of antibodies and the immunological response mediating capabilities of specific cytokines. These engineered pharmacologically-active molecules have, so far, demonstrated better efficacy and reduced toxicity compared to conventional cytokine-based therapies. As a result, immunocytokines are now being investigated for the treatment of a wide array of target indications, including cancers, autoimmune disorders, and certain chronic inflammatory diseases. It is also worth highlighting that this upcoming class of molecules has been demonstrated to work in synergy with certain other established therapeutics, including small molecule drugs (doxorubicin and cytarabine), intact antibodies (atezolizumab, durvalumab, ipilimumab, and nivolumab), radiation therapy, and other immunocytokines. Driven by encouraging clinical trial results, this niche, but emerging domain, is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.

Scope of the Report

The “Immunocytokines Market, 2020-2030” report features an extensive study of the current and future potential of immunocytokines being developed for the treatment of rheumatoid arthritis and various types of cancer. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade. 

Amongst other elements, the report includes:

  • A detailed review of the current market landscape of immunocytokines, providing information on phase of development (phase III, phase II/III, phase II, phase I/II, phase I, and discovery/preclinical stage) of lead candidates, type of therapy (monotherapy and combination therapy), type of cytokine used (IL, IFN, TGF-β, TNF, and others), type of antibody used (anti-CD20, anti-CEA, anti-CTLA-4, anti-DNA, anti-EDA, anti-EDB, anti-FAP, anti-GC2, anti-Her2, anti-KS, anti-PD-L1, anti-PD-1, anti-TA-MUC1, and anti-Tenascin-C), target disease indications (blood cancer, brain cancer, breast cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, lung cancer, prostate cancer, renal cancer, rheumatoid arthritis, skin cancer, undisclosed solid tumors, and others), and route of administration (intravenous, intratumoral, subcutaneous, and others). In addition, the report presents the details of the companies developing these immunocytokines, including information on year of establishment, company size, and location of headquarters.
  • Tabulated profiles of prominent immunocytokine developers. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments, and an informed future outlook.
  • An analysis of recent developments in the field of immunocytokines. It includes partnerships inked by various stakeholders in this domain, during the period between January 2016 and October 2020, covering clinical trial agreements, licensing agreements, mergers and acquisitions, research agreements, research and development agreements, and others. In addition, the report features an analysis of the investments made, including debt funding, equity, venture capital financing, capital raised from IPOs and subsequent offerings, at various stages of development, in companies that are focused on developing immunocytokines.
  • An in-depth analysis of completed, ongoing, and planned clinical studies of various immunocytokines, based on various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication, and key geographical regions.
  • A list of key opinion leaders (KOLs) within this domain, and detailed 2×2 matrices to assess the relative experience of key individuals who were shortlisted based on their contribution (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation (highlighting the geographical locations of eminent scientists/researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations, and strength of professional network (based on information available on LinkedIn).

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities. Based on various parameters, such as disease prevalence, anticipated adoption of immunocytokines, and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] target disease indications (cervical cancer, cholangiocarcinoma, esophageal cancer, gallbladder cancer, head and neck cancer, melanoma, non-small cell lung cancer, rheumatoid arthritis, and soft tissue sarcoma), [B] routes of administration (intravenous, intratumoral, and subcutaneous), and [C] key geographical regions (US, Canada, Germany, UK, France, Italy, Spain, China, Japan, South Korea, Australia, Brazil, Argentina, Israel, and Turkey). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Stephen Gillies, President and CEO, Provenance Biopharmaceuticals
  • Patrik Kehler, Senior Director Scientific and Business Development, Glycotope

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players engaged in the development of immunocytokines?
  • Which cancer indications can be treated with immunocytokines?
  • Which partnership models are commonly adopted by stakeholders engaged in this domain?
  • What are the investment trends in this industry?
  • Which are the most active clinical trial centers?
  • Who are the key opinion leaders that can help you drive your development efforts?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Table of Contents

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

3.1. Chapter Overview
3.2. Overview of Cytokines
3.2.1. Engineered Cytokines and Immunocytokines
3.3. Challenges Associated with the Development of Immunocytokines
3.4. Future Perspectives

4.1. Chapter Overview
4.2. Immunocytokines: Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Therapy
4.2.3. Analysis by Type of Cytokine Used
4.2.4. Analysis by Type of Antibody Used
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Phase of Development, Type of Therapy, and Type of Cytokine Used
4.3. Immunocytokines: List of Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size and Geographical Location
4.3.3. Leading Developers: Analysis by Number of Therapies
4.3.4. Regional Analysis of Therapy Developers

5.1. Chapter Overview
5.2. Genopharm
5.2.1. Company Overview
5.2.2. Immunocytokines Portfolio GNP101 GNP201 GNP301
5.2.3. Recent Developments and Future Outlook
5.3. ImmunGene
5.3.1. Company Overview
5.3.2. Immunocytokines Portfolio IGN001 IGN003 IGN004 IGN005 IGN006
5.3.3. Recent Developments and Future Outlook
5.4. Kanaph Therapeutics
5.4.1. Company Overview
5.4.2. Immunocytokines Portfolio KNP-101 KNP-102 Cytokine X-Anti-Target A Cytokine X-Anti-Target B
5.4.3. Recent Developments and Future Outlook
5.5. Merck KGaA
5.5.1. Company Overview
5.5.2. Immunocytokines Portfolio EMD 521873 M7824 M9241
5.5.3. Recent Developments and Future Outlook
5.6. Philogen
5.6.1. Company Overview
5.6.2. Immunocytokines Portfolio Daromun F8IL10 F16IL2 IL12-L19L19 L19IL2 L19TNF
5.6.3. Recent Developments and Future Outlook

6.1. Chapter Overview
6.2. Recent Developments: Partnerships and Collaborations
6.3. List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year of Partnership and Type of Partner
6.3.4. Most Active Players: Analysis by Number of Partnerships
6.3.5. Regional Analysis Intercontinental and Intracontinental Agreements
6.4. Recent Developments: Types of Funding
6.5. Funding and Investment Analysis
6.5.1. Analysis by Number of Funding Instances (Cumulative), 2016-2020
6.5.2. Analysis by Amount Invested
6.5.3. Analysis by Type of Funding
6.5.4. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
6.5.5. Investment Summary by Region

7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Immunocytokines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Recruitment Status
7.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
7.3.5. Analysis by Study Design
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Most Active Players: Analysis by Number of Registered Trials
7.3.8. Emerging Focus Areas
7.3.9. Analysis by Trial Phase and Target Disease Indication
7.3.10. Geographical Analysis by Number of Clinical Trials
7.3.11. Geographical Analysis by Number of Patients Enrolled

8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.3.1. Analysis by Type of Organization (KOL Affiliation)
8.3.2. Geographical Distribution of KOLs
8.4. Prominent KOLs
8.5. KOL Benchmarking: Assessment versus Third Party (ResearchGate Score)
8.6. Most Active KOLs
8.6.1. KOL Profile: A (Maastricht University)
8.6.2. KOL Profile: B (Centre Léon Bérard)
8.6.3. KOL Profile: C (Eberhard Karls University)
8.6.4. KOL Profile: D (Istituto Clinico Humanitas)
8.6.5. KOL Profile: E (Washington University in St. Louis)

9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Immunocytokines Market, 2021-2030
9.4. Global Immunocytokines Market, 2021 and 2030: Distribution by Target Disease Indication
9.4.1. Immunocytokines Market for Cervical Cancer, 2021-2030
9.4.2. Immunocytokines Market for Cholangiocarcinoma, 2021-2030
9.4.3. Immunocytokines Market for Esophageal Cancer, 2021-2030
9.4.4. Immunocytokines Market for Gallbladder Cancer, 2021-2030
9.4.5. Immunocytokines Market for Head and Neck Cancer, 2021-2030
9.4.6. Immunocytokines Market for Melanoma, 2021-2030
9.4.7. Immunocytokines Market for Non-small Cell Lung Cancer, 2021-2030
9.4.8. Immunocytokines Market for Rheumatoid Arthritis, 2021-2030
9.4.9. Immunocytokines Market for Soft Tissue Sarcoma, 2021-2030
9.5. Global Immunocytokines Market, 2021 and 2030: Distribution by Route of Administration
9.5.1. Immunocytokines Market for Products Requiring Intravenous Administration, 2021-2030
9.5.2. Immunocytokines Market for Products Requiring Intratumoral Administration, 2021-2030
9.5.3. Immunocytokines Market for Products Requiring Subcutaneous Administration, 2021-2030
9.6. Global Immunocytokines Market, 2021 and 2030: Distribution by Geography
9.6.1. Immunocytokines Market in the US, 2021-2030
9.6.2. Immunocytokines Market in Canada, 2021-2030
9.6.3. Immunocytokines Market in Germany, 2021-2030
9.6.4. Immunocytokines Market in the UK, 2021-2030
9.6.5. Immunocytokines Market in France, 2021-2030
9.6.6. Immunocytokines Market in Italy, 2021-2030
9.6.7. Immunocytokines Market in Spain, 2021-2030
9.6.8. Immunocytokines Market in China, 2021-2030
9.6.9. Immunocytokines Market in Japan, 2021-2030
9.6.10. Immunocytokines Market in South Korea, 2021-2030
9.6.11. Immunocytokines Market in Australia, 2021-2030
9.6.12. Immunocytokines Market in Brazil, 2021-2030
9.6.13. Immunocytokines Market in Argentina, 2021-2030
9.6.14. Immunocytokines Market in Turkey, 2021-2030
9.6.15. Immunocytokines Market in Israel, 2021-2030
9.7. Immunocytokines Market, 2021-2030: Product-wise Sales Forecasts
9.7.1. Daromun Target Patient Population Sales Forecast
9.7.2. F8IL10 Target Patient Population Sales Forecast
9.7.3. hu14.18-IL2 Target Patient Population Sales Forecast
9.7.4. L19IL2 Target Patient Population Sales Forecast
9.7.5. L19TNF Target Patient Population Sales Forecast
9.7.6. M7824 Target Patient Population Sales Forecast
9.7.7. RO6874281 Target Patient Population Sales Forecast

10.1. Chapter Overview
10.2. Provenance Biopharmaceuticals
10.2.1. Company Snapshot
10.2.2. Interview Transcript: Stephen Gillies, President and Chief Executive Officer
10.3. Glycotope
10.3.1. Company Snapshot
10.3.2. Interview Transcript: Patrik Kehler, Senior Director Scientific and Business Development


Companies Mentioned

  • AbbVie
  • Abion
  • Agilent Technologies
  • Alopexx Oncology
  • Anglia Ruskin University
  • Antisoma Research
  • Asan Medical Center
  • Assistance Publique – Hôpitaux de Marseille
  • Augusta University
  • Austin Health
  • Bács-Kiskun County Hospital
  • Baptist Health
  • Barts Health NHS Trust
  • Boston Children's Hospital
  • California Cancer Associates for Research and Excellence
  • Calvary Central Districts Hospital
  • Catalan Institute of Oncology
  • Celgene
  • Center Georges - François Leclerc
  • Centre Hospitalier Universitaire de Liège
  • Centre Hospitalier Universitaire de Toulouse
  • Centre Léon Bérard
  • Chang Gung Memorial Hospital
  • Charles University
  • China Medical University Hospital
  • Chongqing University Cancer Hospital
  • City of Hope National Medical Center
  • Clínica Universidad de Navarra
  • Cliniques universitaires Saint-Luc
  • Columbia University
  • Columbia University Irving Medical Center
  • Compassionate Care Research Management Group
  • Comprehensive Cancer Centers
  • Cytune Pharma
  • Dana-Farber Cancer Institute
  • Eberhard Karls Universität Tübingen
  • EMD Serono
  • F. Hoffmann-La Roche
  • FirstHealth of the Carolinas
  • Florida Cancer Specialists & Research Institute
  • Fondazione IRCCS- Istituto Nazionale dei Tumori
  • Fox Chase Cancer Center
  • Fudan University
  • Genopharm
  • GI Innovation
  • Gilead Sciences
  • Glycotope
  • GZA Ziekenhuizen
  • H. Lee Moffitt Cancer Center & Research Institute
  • Helios Klinikum Bad Saarow
  • Henry Ford Health System
  • Highlands Oncology Group
  • Hôpital Cochin
  • Hospices Civils de Lyon
  • Hospital Clínic de Barcelona
  • Hospital Universitario HM Sanchinarro
  • Hospital Universitario Madrid Sanchinarro
  • Hospital Universitario Virgen del Rocío
  • Hospital Universitario Virgen Macarena
  • Icahn School of Medicine at Mount Sinai
  • IGM Biosciences
  • ImmunGene
  • Immunomedics
  • Insitute de Cancérologie de I’Quest 
  • Institut Bergonie
  • Institut Català d'Oncologia
  • Gustave Roussy
  • Institut Jean Godinot
  • Instituto do Câncer de São Paulo
  • IRCCS Istituto Clinico Humanitas
  • IRCCS Ospedale San Raffaele
  • Istituto Europeo di Oncologia
  • Istituto Oncologico Veneto
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST
  • Istituto Toscano Tumori
  • Janssen Biotech
  • Jeroen Bosch Ziekenhuis
  • Kadmon
  • Kanaph Therapeutics
  • Kindai University
  • King's College London
  • Kymab
  • Maastricht University
  • Mayo Clinic
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Merck KGaA
  • Methodist Health System
  • Mount Sinai Medical Center
  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy
  • National Cancer Institute
  • National Cheng Kung University Hospital
  • National Taiwan University Hospital
  • NEXT Oncology
  • Novartis
  • Oklahoma City University
  • Olivia Newton-John Cancer Research Institute
  • OSE Immunotherapeutics
  • Peter MacCallum Cancer Centre
  • Philochem
  • Philogen
  • Policlinico Universitario Agostino Gemelli
  • Provenance Biopharmaceuticals
  • Ronald Reagan UCLA Medical Center
  • Roswell Park Comprehensive Cancer Center
  • Samsung Medical Center
  • Sarah Cannon Research Institute
  • Sarcoma Oncology Center
  • Seoul National University Bundang Hospital
  • Severance Hospital
  • Shenogen Pharma Group
  • Sidney Kimmel Comprehensive Cancer Center
  • Simcere
  • Spectrum Pharmaceuticals
  • St Vincent's Hospital Melbourne
  • St. Joseph's Hospital and Medical Center
  • START Center for Cancer Care
  • Sun Yat-sen University Cancer Center
  • Taipei Veterans General Hospital
  • TCRCure Biopharma
  • Texas Oncology
  • The Catholic University of Korea
  • The Center for Cancer and Blood Disorders
  • The University of Sydney
  • The University of Texas MD Anderson Cancer Center
  • The University of Texas Southwestern Medical Center
  • UC Davis Comprehensive Cancer Center
  • Università di Pisa
  • Universitair Ziekenhuis Antwerpen
  • Universitair Ziekenhuis Brussel
  • Universitair Ziekenhuis Gent
  • Universitair Ziekenhuis Leuven
  • Universitätsklinikum Münster
  • University of California, Irvine Medical Center
  • University of Chicago Medical Center
  • University of Cincinnati
  • University of Colorado Health
  • University of Kansas Medical Center Research Institute
  • University of Maryland
  • University of Pittsburgh Medical Center
  • University of Western Australia
  • Vall d'Hebron Institute of Oncology
  • Valor Biotherapeutics
  • Vanderbilt University Medical Center
  • Virginia Cancer Specialists
  • Washington University in St. Louis
  • Xinqiao Hospital
  • Y-Biologics